Analysis of Novel Prostate Cancer Biomarkers and their Predictive Utility in an Active Surveillance Protocol
Abstract
The Research Project supported by this DOD PCRP Physician Research Training Award investigates novel biomarkers for prostate cancer detection and prediction of disease outcome. This first year of my DOD PCRP PRTA has been very productive from both a translational laboratory and clinical research standpoint. In this first annual reporting period, we have begun to investigate our list of biologically relevant candidate prostate cancer biomarkers and have demonstrated promising results. We have also begun to investigate the expression of these markers in prostate cancer tissue and normal prostate using immunohistochemistry. One of the investigated proteins, Tissue Inhibitor of Matrix Metalloproteinase Type 1 (TIMP-1) was found to have increased expression in men with Gleason 7 or greater prostate cancer compared to men with Gleason 3+3 disease. Immunohistochemical analysis for TIMP-1 demonstrated greater staining in prostate cancer compared with normal prostate tissue. These initial data suggest that this protein may represent a biomarker which can help distinguish intermediate and high risk disease from low risk disease. In addition to success in our laboratory work, we have also made significant accomplishments in developing a database of our cohort of 469 men on active surveillance for prostate cancer over the past 15 years. Our analysis of this database has demonstrated freedom from intervention of 77% at 5 years and 62% at 10 years. Cancer specific survival was 100% at 10 years and overall survival was 95% at 5 years and 88% at 10 years. We recently presented these data at the American Urological Association national meeting and are currently in the process of writing a manuscript to formally publish our results.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2012
- Accession Number
- ADA566564
Entities
People
- Adam S. Feldman
Organizations
- Massachusetts General Hospital